Every Form 4 that Rigel Pharmaceuticals Inc. (New) (RIGL) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RIGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RIGL filings page.
RIGEL PHARMACEUTICALS INC (RIGL) reports that EVP & Chief Financial Officer Dean L. Schorno exercised employee stock options on September 2, 2026, converting a total of 4,600 option rights into 4,600 shares of common stock at exercise prices of $12.70, $18.70 and $24.20 per share. On September 1, 2026, 928 shares of common stock were delivered or withheld to pay the option exercise price or related tax liability. The option figures include awards that vest monthly over multi‑year periods, and no Rule 10b5‑1 trading plan is reported for these transactions.
RIGEL PHARMACEUTICALS INC (RIGL) executive David A. Santos, EVP and Chief Commercial Officer, had 874 shares of common stock delivered or withheld on September 1, 2026 to satisfy exercise price or tax liability at a reference value of $47.50 per share. Following this transaction, he directly holds 61,622 shares, which include 500 shares acquired under the company’s stock purchase plan. No Rule 10b5-1 trading plan is indicated for this filing.
RIGEL PHARMACEUTICALS INC (RIGL) reported that CEO and President Raul R. Rodriguez had 2,424 shares of common stock returned to the issuer on September 1, 2026 as a payment of exercise price or tax liability by delivering or withholding securities. The transaction price was $47.50 per share, and his directly held common stock position after this adjustment was 273,362 shares. A related footnote states that this reflects the return to the issuer of 3,807 shares previously reported as acquired under the issuer's employee stock purchase plan. No Rule 10b5-1 trading plan is reported for this transaction.
RIGEL PHARMACEUTICALS INC (RIGL) reported that executive vice president, general counsel, chief compliance officer and corporate secretary Raymond J. Furey had 877 shares of common stock disposed of on September 1, 2026 as a payment of exercise price or tax liability by delivering or withholding securities at $47.50 per share. After this transaction, he directly holds 50,559 shares of common stock, which includes 500 shares acquired under the issuer's stock purchase plan.
HANNAH ALISON L. reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Alison L. Hannah received a grant of 24,400 shares of common stock in the form of Restricted Stock Units. These RSUs vest annually over four years from July 8, 2026, with the first vesting on July 8, 2027. Following adjustments, including the cancellation of 5,750 RSUs for no consideration, she holds 35,025 shares of common stock directly.
Rigel Pharmaceuticals director Kamil Ali-Jackson sold 2,500 shares of common stock at $35.00 per share in an open-market transaction. After the sale, she directly holds 10,125 shares. The sale was executed under a Rule 10b5-1 trading plan adopted on November 7, 2025 and, according to the disclosure, the shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than for investment purposes.
RIGEL PHARMACEUTICALS INC executive Raymond J. Furey received a fully vested employee stock option tied to a performance goal. The award covers 7,394 shares of common stock at an exercise price of $22.49 per share. The performance metric was confirmed as met on June 17, 2026, triggering vesting, and the option expires on January 29, 2035. This is a compensation-related grant, not an open-market share purchase or sale.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported a performance-based stock option grant that became fully vested on June 17, 2026. The award covers 31,700 shares of common stock under an employee stock option, with an exercise price of $22.49 per share and an expiration date of January 29, 2035. The filing shows this as a compensation-related acquisition, not an open-market buy or sale, and lists 31,700 derivative shares held following the transaction.
Rigel Pharmaceuticals EVP and Chief Medical Officer Lisa Rojkjaer reported the vesting of previously granted performance-based stock options. On June 17, 2026, performance metrics were determined to be met for options covering 9,375 shares at an exercise price of $14.90 and 7,394 shares at $22.49.
Both option grants became fully vested on June 17, 2026. The 9,375-share grant was originally made on March 27, 2024 and adjusted for a one-for-ten reverse stock split effective June 27, 2024, while the 7,394-share grant was made on January 29, 2025.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported the acquisition of an employee stock option covering 7,394 shares of common stock. The option was originally granted on January 29, 2025 with an exercise price of $22.49 per share.
The award carried a performance-based vesting condition and was not reportable until that metric was satisfied. On June 17, 2026, the company determined the performance metric had been met, and the option became fully vested, leaving Schorno with 7,394 option shares following the transaction.
RIGEL PHARMACEUTICALS EVP and Chief Commercial Officer David A. Santos reported a performance-based stock option award covering 7,394 shares of common stock. The option has an exercise price of $22.49 per share and an expiration date of January 29, 2035.
The award was originally granted on January 29, 2025 with a performance-based vesting condition, and it became fully vested on June 17, 2026 when the company determined that the performance metric had been met.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno exercised stock options and settled related taxes in shares. On June 1, 2026, he exercised options for 2,181 shares of common stock at $12.70 per share and 1,200 shares at $18.70 per share. To cover tax obligations, 928 shares of common stock were disposed of at a value of $29.86 per share, a tax-withholding transaction rather than an open-market sale. Following these transactions, he directly held 78,790 shares of Rigel common stock. The filing also notes all share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.
RIGEL PHARMACEUTICALS INC executive David A. Santos, EVP and Chief Commercial Officer, reported a small share disposition related to taxes. On this date, 874 shares of common stock were delivered at $29.86 per share to cover tax obligations. After this tax-withholding event, Santos directly holds 61,996 shares of common stock, indicating that his overall ownership position remains largely unchanged.
RIGEL PHARMACEUTICALS INC EVP and Chief Medical Officer Lisa Rojkjaer reported a tax-related share disposition. On June 1, 2026, 850 shares of Common Stock were transferred at $29.86 per share to cover an exercise price or tax liability by delivering securities.
After this transaction, she directly owned 34,003 shares of Rigel common stock. The filing reflects a tax-withholding disposition rather than an open-market purchase or sale.
RIGEL PHARMACEUTICALS INC CEO and President Raul R. Rodriguez reported a Form 4 transaction involving a tax-related share disposition. On June 1, 2026, 2,424 shares of Common Stock were delivered at $29.86 per share to satisfy tax obligations. After this transaction, Rodriguez directly holds 279,593 shares of Common Stock, indicating the event reflects routine tax withholding rather than an open-market trade.
RIGEL PHARMACEUTICALS INC executive Raymond J. Furey reported a small tax-related share disposition. On June 1, 2026, 877 shares of common stock were delivered at $29.86 per share to cover tax obligations, a non‑market transaction classified as a tax-withholding disposition. Following this, he directly holds 50,936 common shares, indicating the adjustment is minor relative to his remaining position.
RIGEL PHARMACEUTICALS INC director Ali-Jackson Kamil reported an open-market sale of 2,500 shares of Common Stock on May 26, 2026, at an average price of $29.17 per share. Following the sale, the director directly holds 12,625 shares. The transaction was effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Wasman Jane reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Jane Wasman received an equity grant of 5,750 shares of Common Stock. The award is structured as Restricted Stock Units that will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues serving on the Board of Directors.
Following this grant, her direct holdings increase to 18,250 shares, reflecting routine, compensation-related equity rather than an open-market stock purchase.
RIGEL PHARMACEUTICALS INC director Walter H. Moos received an equity award. On 2026-05-15, he was granted 5,750 shares of Common Stock at a grant price of $0.00 per share through a Restricted Stock Unit (RSU) award.
The footnote states these shares will be acquired only when the RSUs fully vest on the date prior to the company’s next Annual Meeting, as long as he continues serving on the Board of Directors. After this award, his direct holdings are 18,472 Common Stock shares.
MILLER MICHAEL PATRICK reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Michael Patrick Miller reported an equity grant of 5,750 shares of Common Stock via Restricted Stock Units. The award has a grant price of $0.00 per share because it is a compensation grant, not a market purchase.
According to the footnote, these Restricted Stock Units will fully vest on the date prior to the company’s next Annual Meeting, as long as Miller continues serving on the Board of Directors. After this grant, he holds 5,937 shares of Common Stock directly.
LAPOINTE ANTHONY GREGG reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Anthony Gregg Lapointe reported an equity compensation grant of 5,750 shares of Common Stock, recorded at a price of $0.00 per share. These shares are tied to a Restricted Stock Unit award that will fully vest on the date prior to the company’s next Annual Meeting, if he continues serving on the Board of Directors. Following this award, Lapointe’s reported direct holdings total 18,250 shares of Common Stock.
RIGEL PHARMACEUTICALS INC director Alison L. Hannah received an equity award in the form of Restricted Stock Units. The filing shows a grant of 5,750 shares of Common Stock at a price of $0.00 per share, reflecting a compensation-related award rather than a market purchase.
These shares are to be acquired upon vesting of the Restricted Stock Unit award. According to the terms, the units will fully vest on the date prior to the company’s next Annual Meeting, as long as she continues to serve on the Board of Directors. After this grant, her direct Common Stock holdings reported in this filing total 16,375 shares.
Rigel Pharmaceuticals director Mark W. Frohlich was granted 5,750 restricted stock units of common stock at no cost. These units will be acquired upon vesting and are scheduled to fully vest on the date prior to the company’s next annual meeting, subject to his continued service on the board. Following this equity award, Frohlich beneficially owns 7,000 shares of Rigel’s common stock.
Ali-Jackson Kamil reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC director Kamil Ali-Jackson received a stock grant tied to board service. The Form 4 shows an award of 5,750 shares of Common Stock at no cash cost, delivered as Restricted Stock Units. These units will fully vest on the date prior to the company’s next Annual Meeting, as long as the director continues serving on the Board. After this grant, the director holds 15,125 shares of Common Stock directly.
Rigel Pharmaceuticals director Walter H. Moos reported option and share transactions. On February 20, 2026, he exercised a stock option for 4,000 shares of common stock at $24.00 per share through a derivative exercise or conversion.
On the same date, he sold 4,000 shares of common stock in an open-market or private transaction at $36.36 per share. After these transactions, he directly owned 12,722 shares of Rigel Pharmaceuticals common stock. The reported numbers reflect a prior one-for-ten reverse stock split.
Rigel Pharmaceuticals executive Raymond J. Furey reported an equity compensation award in the form of Restricted Stock Units tied to the company’s common stock. The award covers 19,497 shares, reflected as an acquisition with no cash price because it is a grant, not an open-market purchase.
These Restricted Stock Units will vest quarterly over a three-year period, with the first quarterly vesting scheduled for March 31, 2026. Following this award, Furey is shown as having 51,813 shares of common stock in direct ownership, illustrating his ongoing equity alignment with the company.
Rojkjaer Lisa reported acquisition or exercise transactions in this Form 4 filing.
RIGEL PHARMACEUTICALS INC reported that EVP and Chief Medical Officer Lisa Rojkjaer received a grant of 18,894 shares of common stock in the form of Restricted Stock Units. These RSUs will vest quarterly over three years, starting with the first vesting on March 31, 2026. After this award, she is reported to beneficially own 34,853 shares of common stock directly.
Rigel Pharmaceuticals CEO and President Raul R. Rodriguez reported an equity award on common stock. He acquired a grant of 53,915 shares through a Restricted Stock Unit award at a stated price of $0.00 per share. According to the award terms, these Restricted Stock Units will vest quarterly over three years, with the first vesting date on March 31, 2026. After this grant, Rodriguez directly owns 282,017 shares of common stock.
Rigel Pharmaceuticals EVP & Chief Financial Officer Dean L. Schorno reported an equity award of company stock. He acquired 20,636 shares of common stock through a grant of restricted stock units at a stated price of $0.00 per share. Following this grant, he directly holds 76,337 common shares.
The award vests over time rather than all at once. The restricted stock units are scheduled to vest quarterly over three years, with the first quarterly vesting date on March 31, 2026. As each portion vests, the corresponding shares of common stock will be delivered to him.
Santos David A reported acquisition or exercise transactions in this Form 4 filing.
Rigel Pharmaceuticals executive David A. Santos reported an equity grant. He was awarded 19,430 shares of common stock at a price of $0.00 per share, tied to a Restricted Stock Unit award. The RSUs will vest quarterly over three years, starting on March 31, 2026, increasing his direct ownership to 62,870 shares as they vest.
Rigel Pharmaceuticals executive Dean L. Schorno reported a tax-related share disposition. As EVP & Chief Financial Officer, he had 3,546 shares of Rigel Pharmaceuticals common stock withheld on February 10, 2026 to cover tax obligations at a price of $34.62 per share.
After this tax-withholding disposition, he directly beneficially owned 55,701 shares of Rigel Pharmaceuticals common stock. The filing characterizes the transaction as payment of a tax liability by delivering securities, rather than an open-market sale.
Rigel Pharmaceuticals executive Raymond J. Furey disposed of 3,546 shares of common stock on February 10, 2026 to satisfy tax obligations. The tax-withholding disposition, reported under transaction code F at a share price of $34.62, left him holding 32,316 shares of Rigel common stock directly.
Rigel Pharmaceuticals executive David A. Santos reported a routine share disposition related to tax withholding. On 02/10/2026, 3,546 shares of common stock were disposed of at $34.62 per share to satisfy tax obligations associated with equity compensation. After this transaction, he directly owned 43,440 shares of Rigel common stock.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported an automatic share disposition related to taxes. On 02/10/2026, 7,607 shares of common stock were withheld at $34.62 per share in a transaction coded “F,” which indicates payment of tax liability by delivering securities.
After this tax-withholding disposition, Rodriguez directly owned 228,102 shares of Rigel Pharmaceuticals common stock. This filing reflects an administrative equity and tax event rather than an open-market purchase or sale.
Rigel Pharmaceuticals executive Lisa Rojkjaer reported a tax-related stock transaction. As EVP and Chief Medical Officer, she disposed of 3,758 shares of common stock on February 10, 2026 through a tax-withholding arrangement at $34.62 per share.
After this transaction, she directly beneficially owned 15,959 shares of Rigel Pharmaceuticals common stock. The transaction was coded as a payment of tax liability by delivering securities, which is typically associated with equity compensation events rather than an open-market sale.
Rigel Pharmaceuticals executive David A. Santos, EVP and Chief Commercial Officer, reported a disposition of common stock. On 02/02/2026, he disposed of 5,718 shares of Rigel common stock at $36.01 per share in a transaction coded "F." After this transaction, he beneficially owned 46,986 shares, held directly. A footnote explains that this balance includes 1,000 shares acquired under the issuer's stock purchase plan.
Rigel Pharmaceuticals executive Dean L. Schorno, EVP & Chief Financial Officer, reported a Form 4 transaction involving company common stock. On 02/02/2026, 5,488 shares of common stock were disposed of in a transaction coded "F" at a price of $36.01 per share.
Following this transaction, Schorno beneficially owned 59,247 shares of Rigel common stock in direct ownership. This total includes 500 shares acquired under Rigel’s stock purchase plan, as noted in the filing’s footnote.
Rigel Pharmaceuticals executive Raymond J. Furey, EVP, GC, CCO & Corp Sec, reported a disposition of common stock. On February 2, 2026, he disposed of 3,968 shares of Rigel common stock at $36.01 per share, reported with transaction code F.
After this transaction, Furey directly beneficially owned 35,862 common shares, which the disclosure notes includes 1,000 shares acquired under Rigel’s stock purchase plan.
Rigel Pharmaceuticals CEO Raul R. Rodriguez reported multiple insider stock transactions. On January 26, 2026, he exercised employee stock options in two 40,000-share lots at $27.40 per share and reported related dispositions of 35,211 and 35,424 common shares at $37 per share.
On February 2, 2026, he reported an additional disposition of 14,110 common shares at $36.01 per share. After these transactions, he directly beneficially owned 235,709 Rigel common shares, including 1,000 shares acquired under the company’s stock purchase plan. All share amounts reflect a one-for-ten reverse stock split effective June 27, 2024.
Rigel Pharmaceuticals director receives new stock option grant. Director Michael Patrick Miller was awarded a stock option for 12,000 shares of Rigel common stock on February 1, 2026, with an exercise price of $34.86 per share. The option vests in equal monthly installments from February 1, 2026 until the annual meeting at which he is first scheduled to be considered for election by stockholders, conditioned on his continued service on the board.
Rigel Pharmaceuticals' EVP & Chief Financial Officer reported option exercises and updated holdings. On 12/22/2025, the officer exercised three employee stock options (code M), acquiring 1,987 shares at $20, 2,846 shares at $24.2, and 1,667 shares at $18.7 per share.
Following these transactions, the officer beneficially owned 64,235 shares of Rigel common stock, which includes 500 shares acquired under the company’s stock purchase plan. The filing also shows remaining employee stock options covering 14,262, 17,153, and 10,832 shares, with expiration dates ranging from 01/23/2029 to 01/26/2033. All share numbers reflect a one-for-ten reverse stock split effective June 27, 2024, and the options vest in equal monthly installments over four years from their respective vesting commencement dates.